Malaysia Becomes the Eighth Country that Approves BIBP’s COVID-19 Vaccine for Conditional Registration and Marketing

Noor Hisham Abdullah, Director General of Health Malaysia, announced on July 16 that Malalysia’s National Pharmaceutical Control Bureau（NPCB） had approved the Inactivated COVID-19 Vaccine (Vero Cell) developed and produced by Beijing Institute of Biological Products Co., Ltd. (BIBP), China National Biotec Group Company Limited (CNBG), Sinopharm (hereinafter referred to as “BIBP’s COVID-19 vaccine”) for conditional registration and marketing, 

      It makes Malaysia become the eighth country in the world that approves BIBP’s COVID-19 vaccine for registration. Earlier, the vaccine has been approved for registration in the UAE, Bahrain, China, Bolivia, Seychelles, Thailand and Turkmenistan, respectively.

      To date, BIBP’s COVID-19 vaccine has been approved for emergency use or market access in 87 countries, regions and international organizations, received the procurement requests from more than 100 countries, and vaccination has covered 196 country population. It is also the first COVID-19 vaccine in China that has been included into Emergency Use Listing (EUL) by WHO and granted GMP certification by EU.

      With the completion and production of the world’s largest COVID-19 vaccine production base in CNBG, the overall annual production capacity of BIBP’s COVID-19 vaccine has exceeded 5 billion doses, enabling China to contribute more strength to the global fight against the COVID-19 and the building of a community of common health for mankind, to a greater extent and in a broader scope.